What is not yet clear from the reports coming from ATX thus far is whether the two apparent remissions reported by them are due to additive/syngergic effects of their tyrosine kinase inhibitor when used in conjunction with gemcitabine and nab-paclitaxel (link to trial design below). When you read the rather dated NEJM paper referenced in their latest ASX release (NEJM link below) you will see that in general, when gemcitabine and nab-paclitaxel are used as chemotherapeutic agents in the treatment of pancreatic cancer, extension of survival appears to be a matter of months, and that there are significant drug-related side-effects associated with their use. So just maybe the ATX tyrosine kinase inhibitor could eventually prove to have significant clinical benefit when used in conjunction with lower doses of one or both of these 2 drugs. Which might lead to fewer serious side effects impacting on patients if the ATX tyrosine kinase inhibitor itself proves to be largely free of side effects. Which would be a nice achievement.
Whilst some/all of the above comments might be construed as mere conjecture, my hope, like that of others here, is that Syntara’s SNT-5505 might eventually show useful therapeutic benefit if introduced into human pancreatic cancer treatment protocols. Which would also be a nice acheivement.
So it would also be nice to see some movement at the station sooner rather than later.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)